Browse Reports

MariMed Inc. operates as a multi-state cannabis operator in the United States, headquartered in Norwood, Massachusetts. The company owns and manages state-licensed facilities for cultivation, production, and dispensing of medicinal and adult-use cannabis. It has developed proprietary brands of cannabis products including flower, concentrates, edibles, and precision-dosed items. MariMed distributes products wholesale to hundreds of dispensaries and operates its own retail dispensaries under the Thrive™ brand in multiple states. The company is fully vertically integrated in Illinois, Maryland, Massachusetts, and Delaware, holding 33 cannabis licenses across six states. Its strategic growth plan focuses on expanding brand revenue, broadening distribution, and increasing retail footprint through new licenses and acquisitions. MariMed invests in marketing, customer loyalty programs, and retail staff training to enhance customer experience. The company reported a net loss for fiscal 2025 and maintains liquidity with $6.6 million in cash and equivalents as of Q3 2025. It faces competition from other multi-state and single-state cannabis operators but leverages proprietary brands and operational expertise as competitive advantages [S1][S2].

Bolt Biotherapeutics, Inc. operates as a clinical-stage biotherapeutics company specializing in oncology drug development. The company focuses on advancing its pipeline of immuno-oncology candidates, including BDC-4182 and BDC-3042, which have shown promising clinical activity in early trials. Bolt's business model centers on clinical development and eventual commercialization of novel cancer therapies. The company is publicly traded on the Nasdaq Capital Market under the ticker BOLT. Financial disclosures indicate ongoing investment in R&D with reported revenues primarily from collaborations or licensing, alongside operating losses typical of clinical-stage biotech firms. Bolt has taken steps to manage operating expenses through workforce reductions and restructuring initiatives in 2025.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for solid tumors and serious diseases. Its lead product candidate, certepetide, activates a tumor-specific uptake pathway to improve penetration and accumulation of co-administered anti-cancer drugs in tumors while sparing normal tissues. Certepetide also modulates the tumor microenvironment to enhance immunotherapy susceptibility and inhibit metastasis. The company has conducted multiple Phase 2 clinical trials globally in various solid tumor types and collaborates with partners such as Catalent on preclinical research. Lisata has no approved products and has not generated product revenue. The company has incurred significant net losses since inception and maintains liquidity through cash and equivalents, but anticipates the need for additional financing to continue operations. In March 2026, Lisata entered into a merger agreement with Kuva Labs Inc., which includes a tender offer and contingent value rights related to regulatory milestones for certepetide. Completion of the merger is subject to customary conditions and will result in Lisata becoming a privately held company and delisting from Nasdaq.

Runway Growth Finance Corp. is an externally managed, non-diversified closed-end management investment company structured as a Business Development Company (BDC) and regulated investment company (RIC). It provides senior secured loans and hybrid debt and equity financing to high growth-potential companies primarily in technology, healthcare, business services, financial services, and select consumer sectors. The company aims to generate returns through current income on loans and capital gains on equity positions. Managed by Runway Growth Capital LLC, the company had an investment portfolio valued at $927.4 million and net assets of $485.0 million as of December 31, 2025. Its debt portfolio is predominantly senior secured loans with a dollar-weighted annualized yield of 14.6% for 2025. The company is actively engaged in capital markets, including recent note offerings and redemptions.

CoastalSouth Bancshares, Inc. operates as a financial institution with a focus on interest-earning assets and liabilities management. The company’s financial performance is primarily driven by net interest income, which increased in 2025 due to growth in average loans and earning assets, alongside a decrease in interest expense from lower rates on liabilities. The company employs derivative instruments such as interest rate swaps and collars to manage interest rate risk. Its accounting policies adhere to US GAAP and involve significant management judgment, particularly in estimating credit losses and fair value measurements. The company does not currently engage in share repurchases and has no plans for such programs.

Resolute Holdings Management, Inc. is a management company formed in 2024 to provide operating management services to CompoSecure Holdings and other managed companies. CompoSecure Holdings designs and manufactures complex metal and composite financial transaction cards, including innovative products with secure authentication and digital asset storage capabilities under the Arculus platform. The company serves primarily leading banks and payment card issuers in the U.S. and internationally. Resolute Holdings generates recurring management fees based on CompoSecure Holdings’ financial performance under long-term agreements. The business model emphasizes operational performance improvement, strategic acquisitions, and capital markets expertise to drive growth. The company’s financials show a net loss for 2025 but strong liquidity and operational scale. Key risks include reliance on key personnel, customer concentration, supply chain disruptions, technological change, and cybersecurity threats related to digital asset products.

Acurx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing a new class of small molecule antibiotics with a Gram-positive selective spectrum. Its approach targets the bacterial enzyme DNA polymerase IIIC to inhibit DNA replication in Gram-positive bacteria, leading to bacterial cell death. The company’s pipeline includes candidates targeting serious infections such as Clostridioides difficile infection (CDI), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and Bacillus anthracis (anthrax). Acurx has advanced its lead candidate, ibezapolstat, to Phase 3 clinical trials for CDI and is initiating a new clinical trial for recurrent CDI (RCDI). The company has received positive regulatory feedback from the European Medicines Agency (EMA) regarding pediatric use of ibezapolstat. To date, Acurx has not generated product revenue and continues to incur operating losses as it advances its clinical development programs. The company has taken corporate actions such as a 1-for-20 reverse stock split to regain Nasdaq compliance. Financially, as of December 31, 2025, Acurx reported a net loss of $7.97 million and maintains liquidity with a current ratio of 2.54 and cash ratio of 5.97. Management has indicated the need for additional financing to sustain operations.

Horizon Kinetics Holding Corporation operates as an investment advisory and independent research firm through its wholly-owned registered investment advisor, Horizon Kinetics Asset Management LLC. The company employs a fundamental value, contrarian-oriented investment philosophy emphasizing long-term investment horizons. It offers investment strategies through mutual funds, ETFs, private funds, and separately managed accounts. As of December 31, 2025, assets under management totaled approximately $9.6 billion. Horizon Kinetics generates revenue primarily from advisory fees, including management and performance fees, which vary by strategy and account size. The company has no debt and has invested in technology and senior management to enhance client experience and capacity. Its investment approach focuses on companies with predictive attributes, supported by proprietary in-house research. The firm manages a range of funds including the Inflation Beneficiaries ETF, Paradigm Fund, Small Cap Opportunities Fund, Polestar Funds, Equity Opportunities Fund, and Multi-Strategy Funds, alongside separately managed accounts. The company employs 81 people, including 20 investment professionals, and maintains governance through executive and investment committees. It operates in a competitive environment and is subject to extensive regulatory and compliance requirements.

Liquidmetal Technologies develops and commercializes proprietary bulk amorphous alloys known as Liquidmetal alloys, which have a non-crystalline atomic structure that provides superior performance and processing characteristics compared to traditional crystalline metals. The company designs, develops, and sells custom alloy products and parts to customers in industries such as non-consumer electronics, medical devices, automotive components, and sports goods. Revenue is generated from product sales, tooling and prototypes, and licensing royalties. Manufacturing is primarily outsourced to third-party contract manufacturers, notably Dongguan Yihao Metal Materials Technology Co. Ltd., an affiliate of the company's Chairman. The company formed a joint venture in 2025 to develop a manufacturing facility in Hangzhou, China, aiming to expand production capabilities. The company has a history of operating losses and an accumulated deficit, with net losses continuing in recent periods. Liquidity as of December 31, 2025, is supported by cash, current assets, and lease income from a facility in California. The company faces challenges including long customer adoption cycles, reliance on limited suppliers, competitive pressures from incumbent materials, and geopolitical risks related to manufacturing in China.

TerrAscend Corp. operates as a vertically integrated cannabis company with licensed cultivation, processing, and retail operations in Pennsylvania, New Jersey, Maryland, California, Ohio, and Ontario, Canada. The company manages multiple subsidiaries and operates approximately twenty dispensaries and four cultivation/processing facilities. Its product portfolio includes flower, concentrates, vaporizables, edibles, tinctures, and topicals under proprietary brands such as Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, and Ilera Healthcare, as well as licensed brands Wana and Cookies. The company’s retail stores are primarily branded as The Apothecarium, focusing on customer education and service. TerrAscend’s cultivation facilities operate year-round with multiple harvest cycles to mitigate seasonality. The company’s business is subject to U.S. federal cannabis illegality, impacting tax treatment and regulatory risks. It maintains significant indebtedness and capital-intensive operations, with liquidity ratios indicating moderate short-term financial flexibility as of the end of 2025.

Corvus Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company developing drugs and antibodies targeting critical elements of the immune system. The company relies on third-party organizations for clinical trials, manufacturing, and research activities. It holds licensing agreements with several institutions, including Vernalis, Scripps Research Institute, and Monash University, which involve milestone payments and royalties. The company manages its operations as a single segment focused on drug development and commercialization. As of the end of 2025, Corvus had no commercial products and reported net losses consistent with its clinical-stage status.

Unusual Machines, Inc. operates in the commercial drone industry, manufacturing and selling drone components and drones through a diversified brand portfolio. The company emphasizes onshoring manufacturing in the U.S. to meet National Defense Authorization Act (NDAA) compliance and serves both consumer and enterprise customers. It has developed multiple components approved for the Department of Defense's Blue Framework, supporting defense and commercial applications. The company has expanded its manufacturing footprint with five facilities near Orlando, Florida, producing motors, headsets, and other critical components. Its growth strategy includes organic revenue growth, expanding B2B sales, strategic acquisitions, and investments in the U.S. drone ecosystem. The company competes with large international and domestic manufacturers, differentiating through price-competitive, domestically produced, NDAA-compliant products.

OptimizeRx Corp operates as a digital healthcare technology company that provides targeted marketing and engagement solutions to life sciences brands. Founded in 2006, the company integrates AI and machine learning with proprietary platforms such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver precise, privacy-compliant marketing campaigns to healthcare providers and patients. Its omnichannel network reaches over two million U.S. healthcare providers and millions of patients, facilitating brand engagement and improved patient care. The company has expanded its capabilities through acquisitions, including Medicx Health in 2023, and focuses on transitioning customers to subscription-based models to enhance revenue predictability and profitability. OptimizeRx's technology platform includes data intelligence, cloud infrastructure, and supply-side platform features to optimize ad inventory and campaign management. The company faces risks related to customer concentration, reliance on eRx and EHR platform partners, and financial covenants on its term loan.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) diseases. The company emerged from a merger completed in August 2024, changing its name and ticker symbol to Oruka Therapeutics, Inc. (ORKA). Its lead product candidates, ORKA-001 and ORKA-002, target validated cytokine pathways IL-23p19 and IL-17A/F, respectively, which are central to the pathogenesis of PsO and related conditions. ORKA-001 incorporates YTE half-life extension technology designed to enable infrequent subcutaneous dosing, with ongoing Phase 2a and Phase 2b clinical trials. ORKA-002 has demonstrated a half-life of approximately 75-80 days in Phase 1 trials and is in Phase 2 development for PsO and planned for hidradenitis suppurativa. The company also has a third program, ORKA-003, targeting an undisclosed pathway with potential for indication expansion. Oruka holds exclusive worldwide licenses from Paragon Therapeutics for its lead programs and relies on third-party contract manufacturing organizations, including a license agreement with WuXi Biologics for manufacturing technology. The company has no approved products or revenue to date and has incurred significant net losses. It maintains strong liquidity with cash, short-term investments, and current assets substantially exceeding current liabilities as of December 31, 2025. Oruka faces typical risks of clinical-stage biopharmaceutical companies, including capital requirements, clinical and regulatory uncertainties, competition, reliance on third parties, and intellectual property challenges.

MVB Financial Corp. is a financial holding company organized in 2003, operating mainly through MVB Bank, Inc. The Bank offers a broad range of commercial and retail banking products, including deposit accounts, loans, debit cards, and safe deposit services. It also provides Fintech banking services focused on operational risk management and compliance for corporate Fintech clients across the U.S., particularly in payments, banking-as-a-service, and gaming industries. The company has divested interests in certain subsidiaries such as Trabian Technology and Victor Technologies. Its primary market area for traditional banking is North Central West Virginia and Northern Virginia, with lending also extending to healthcare and SBA borrowers outside this region. The company segments its operations into CoRe Banking (including Fintech), Mortgage Banking, Financial Holding Company activities, and Other professional services and Edge Ventures. The loan portfolio is heavily weighted toward commercial loans, with residential mortgage and consumer loans comprising smaller portions. The company faces competition from a variety of financial institutions, including Fintech-focused banks and neobanks. It employs 403 team members and emphasizes a strong culture, diversity, and employee development. The company is subject to extensive federal and state banking regulations and maintains capital adequacy under the Community Bank Leverage Ratio framework.

HeartBeam, Inc. focuses on transforming cardiac care through a patented 3D ECG technology platform that synthesizes a 12-lead ECG from three-dimensional heart electrical signals. Its flagship product, the HeartBeam System, is the first FDA-cleared cable-free ambulatory 12-lead ECG device designed for arrhythmia assessment outside healthcare facilities. The system includes a small, credit card-sized device, patient and physician software applications, and cloud-based algorithms with cardiologist review. The company is targeting concierge and preventive cardiology markets with a limited launch in early 2026 and is developing expanded indications such as heart attack detection and an extended wear ECG patch. HeartBeam aims to leverage longitudinal ECG data and AI to enhance cardiac screening and prediction. The company had 16 employees at the end of 2025 and reported no revenue but significant net losses. Manufacturing and logistics partnerships are in place to support commercialization.

DUKE Robotics Corp. develops advanced robotic and drone-based systems with applications in military defense and civilian infrastructure maintenance. Founded in 2014, the company shifted focus in 2020 to robotic stabilization systems for military use and drone solutions for electric utility insulator cleaning. It operates through subsidiaries in Israel and Greece, with regulatory approvals enabling European operations. The company collaborates with Elbit Systems for its stabilized weapons drone system marketed as 'Birds of Prey' and generates royalties and commissions from this partnership. Its civilian product, the IC Drone, offers a safer, cost-efficient alternative to traditional high-voltage insulator cleaning methods, with commercial agreements in place with the Israel Electric Corporation. Recent technological advancements include the ICDS2 and the AEROTRACE™ monitoring solution integrating AI analytics. DUKE Robotics faces operational challenges from geopolitical instability in Israel and financial constraints, with limited public market liquidity and trading activity [S1][S2].

RF Acquisition Corp III is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It completed its initial public offering in February 2026, issuing units consisting of ordinary shares and rights to purchase additional shares upon completion of a business combination. The company raised gross proceeds of $100 million, which are held in a trust account. The company’s securities trade on Nasdaq under the symbols RFAM (ordinary shares), RFAMR (rights), and RFAMU (units). As a SPAC, the company currently has no operating business or revenue and is focused on identifying and completing an initial business combination.

Emerald Holding, Inc. operates business-to-business trade shows mainly in the United States, with expanding operations internationally. The company’s portfolio includes market-leading trade show franchises across diverse industry verticals, typically held annually or multiple times per year. Emerald integrates live events with media content, digital tools, data solutions, and e-commerce platforms to create rich customer experiences. The business is organized into one reportable segment comprising three operating lines: Connections (trade shows and live events), Content, and Commerce. The Connections segment is the primary revenue driver, offering exhibitors opportunities to engage buyers and generate sales. The company also operates content marketing websites, digital products, and B2B commerce solutions that complement live events and provide year-round customer engagement. Emerald pursues organic growth by enhancing exhibitor and attendee participation and through acquisitions of leading industry events. Revenues are primarily generated from selling exhibit space, sponsorships, conferences, and attendee fees, with payments typically collected in advance. The company’s business model benefits from favorable cash flow dynamics due to advance payments and timing of expenses. Key risks include cybersecurity threats, economic and industry cyclicality, inflation and interest rate pressures, and seasonal revenue variability.

Quest Resource Holding Corp is a publicly traded company listed on Nasdaq under the ticker QRHC. The company is incorporated in Nevada with principal offices in Texas. It operates with a financial structure that includes a revolving credit facility secured by its subsidiaries' assets. The company has reported net losses in recent fiscal periods and maintains liquidity with a current ratio of 1.3 as of the end of 2025. Detailed descriptions of its business model, industry classification, and product offerings are not disclosed in the available SEC filings or recent news reports.

First Northern Community Bancorp operates as a community bank primarily in northern and central California counties. It offers deposit products, commercial, consumer, and real estate loans, and additional financial services including equipment leasing and payroll services. The bank’s revenue is mainly derived from interest income on loans and investments. It maintains FDIC insurance coverage for deposits and has a diversified deposit base. The company reported consolidated assets near $1.91 billion and equity of approximately $212 million as of the end of 2025.

JOINT Corp is a franchisor of chiropractic clinics operating a private pay, non-insurance, cash-based business model. The company focuses on expanding its franchise network across North America and potentially internationally. As of September 30, 2025, the company and its franchisees operated 962 clinics, with the majority franchised. The company generates revenue primarily from royalty fees, franchise fees, advertising fund revenue, and IT-related income. It has been actively refranchising its company-owned clinics, selling clusters of clinics to franchisees and third parties to leverage its franchise growth capabilities. The company maintains a robust management information system and cybersecurity framework, including ISO 27001 certification and compliance with HIPAA and PCI DSS standards. Financially, the company reported revenues of $39.7 million for the nine months ended September 30, 2025, with a net loss from continuing operations of $1.2 million and adjusted EBITDA of $3.3 million. Liquidity remains adequate with $23.6 million in cash and a current ratio of 1.59 as of December 31, 2025. The company faces risks related to regulatory compliance, cybersecurity, labor costs, and execution of its refranchising strategy.

Bar Harbor Bankshares operates as a bank holding company with a focus on providing banking and financial services to customers in a three-state region, primarily Maine and New Hampshire. The company generates revenue mainly from net interest income on loans and investment securities, supplemented by noninterest income from fees and ancillary financial services. In 2025, it completed the acquisition of Guaranty Bancorp, Inc., adding significant assets, loans, deposits, and branches, thereby expanding its regional footprint. The company maintains strong liquidity and capital positions, with a diversified loan portfolio including commercial, residential real estate, and consumer loans. It actively manages credit risk and liquidity through established policies and maintains a history of paying dividends to shareholders.

Sachem Capital Corp. operates as a Connecticut-based real estate finance company and REIT, focusing on originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property. The company’s loans, often referred to as 'hard money loans,' are typically used by real estate investors and developers to finance acquisition, renovation, development, or improvement of residential and commercial properties held for investment or sale. The company generates revenue primarily from interest and fees associated with these loans. Its underwriting process emphasizes property valuation, borrower creditworthiness, and project risk assessment, supported by independent appraisals and market data. The loan portfolio is geographically concentrated in the northeastern and southeastern United States, with significant exposure in Connecticut, Florida, Massachusetts, and New York. Management aims to grow the loan portfolio while preserving capital and delivering attractive risk-adjusted returns to shareholders through dividends. The company also engages in opportunistic real estate acquisitions and development when value creation opportunities arise.

Ponce Financial Group, Inc. is a financial holding company and the parent of Ponce Bank, N.A., a community bank operating primarily in New York City. The company’s business centers on multi-family real estate loans, construction lending, and other commercial real estate financing. It operates under regulatory capital and liquidity requirements and is subject to federal and state banking regulations. The company’s loan portfolio is exposed to risks from rent control legislation, changes in tax incentive programs for construction, and regulatory scrutiny on commercial real estate lending concentrations. The company also faces operational risks related to technology dependence and cybersecurity. Its business strategy focuses on serving minority and immigrant communities and maintaining a strong reputation in its markets.

Jefferson Capital, Inc. operates as a debt recovery and portfolio management company, purchasing nonperforming and credit-deteriorated consumer loan portfolios from a diverse set of credit originators including banks, fintech platforms, and credit card issuers. The company uses proprietary statistical models to value and manage these portfolios, employing legal and voluntary collection channels to maximize recoveries. It operates across multiple geographies including the U.S., Canada, the U.K., and Latin America, with a workforce of over 1,100 employees. The company completed its IPO in June 2025 and has a complex holding company structure. It faces competition primarily from other debt purchasers and outsourced receivables management providers, with regulatory compliance being a significant operational consideration. Seasonality affects deployment and collection timing, with the fourth quarter being the busiest for portfolio purchases and early-year months strongest for collections. The company completed a significant credit card portfolio acquisition from Bluestem in late 2025. Jefferson Capital maintains significant indebtedness and is subject to restrictive covenants that may affect its financial flexibility.

Nektar Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on developing immunomodulatory agents for autoimmune diseases and cancer. Its drug pipeline includes rezpegaldesleukin, NKTR-255, NKTR-0165, and NKTR-0166, with ongoing clinical trials and preclinical development. The company collaborates with pharmaceutical partners such as Bristol-Myers Squibb and Eli Lilly and has monetized certain assets including its manufacturing facility. Nektar finances its operations primarily through collaboration payments, equity offerings, and milestone payments. The company operates as a single business segment and manages its resources accordingly.

BRT Apartments Corp. operates as a real estate investment trust (REIT) specializing in multi-family residential properties. The company owns and operates a portfolio of 31 multi-family properties across 11 states, primarily in the Southeastern United States and Texas. BRT’s business model includes wholly owned properties, equity interests in joint ventures, and preferred equity investments. The company’s leases are generally short-term, typically one year or less, which partially mitigates inflation impact but does not eliminate it. BRT finances its properties primarily through fixed-rate mortgage debt and maintains a credit facility to support acquisitions, capital improvements, and working capital needs. The company actively manages its portfolio through acquisitions, refinancing, and dispositions, with recent acquisitions including a 214-unit property in Auburn, Alabama, and a 150-unit property in Savannah, Georgia. BRT pays quarterly dividends and has a share repurchase program. The company faces operational challenges from inflationary cost pressures, competitive rental markets requiring concessions, and significant upcoming mortgage maturities requiring refinancing or capital raising.

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its proprietary oral vaccine platform. The company operates primarily through government contracts and collaborations, including a significant licensing agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate. Vaxart's financials for fiscal year 2025 show substantial revenue growth driven by government contracts, alongside ongoing research and development expenditures. The company finances its operations mainly through equity offerings and government funding, with liquidity ratios indicating moderate short-term financial stability.

John Marshall Bancorp, Inc. operates as the holding company for John Marshall Bank, a Virginia-chartered commercial bank focused on serving small to medium-sized businesses, professionals, non-profits, and individuals primarily in the Washington, D.C. metropolitan area. The bank offers a broad range of financial products including commercial and real estate loans, SBA 7(a) loans, deposit accounts, treasury and cash management services, and digital banking platforms. The company’s market area is characterized by strong economic growth, high median household income, and a well-educated population. The bank competes by emphasizing local decision-making, personalized service, and a disciplined credit culture. As of December 31, 2025, the company had $2.33 billion in assets, $1.97 billion in gross loans, and $1.97 billion in deposits. The company’s strategy includes hiring experienced bankers, expanding selectively in high-growth markets, maintaining strong asset quality, and leveraging technology to enhance customer experience while controlling costs.

Harvard Bioscience, Inc. develops and sells technologies, products, and services that support life science research, drug and therapy discovery, bioproduction, and preclinical testing. The company serves a global customer base including academic institutions, government labs, pharmaceutical and biotechnology companies, and CROs. It operates primarily in the US, Europe, and China, selling through direct and distributor channels. The business is organized into two product families: Cellular and Molecular Technology (CMT), which supports molecular and cellular research and bioproduction, and Preclinical, which supports preclinical drug development testing. The company also distributes third-party products. Harvard Bioscience is pursuing a strategic transformation to become a leading enabler of Translational Medicine, focusing on bridging in vivo and in vitro research, expanding consumables and software revenue, and improving operational efficiency through initiatives such as Project Viking, a manufacturing consolidation plan. The company invests in research and development to maintain and expand its product portfolio and has a manufacturing footprint in the US and Europe with flexible capabilities.

Barinthus Biotherapeutics plc. focuses on developing antigen-specific immune tolerance therapies for autoimmune and inflammatory diseases. Its proprietary SNAP-TI platform uses synthetic nanoparticles to modulate T cell responses, aiming to restore immune tolerance. The lead product candidate, VTP-1000, is designed to treat celiac disease by suppressing immune response to gluten and is in Phase 1 clinical trials. The company also has a legacy pipeline including VTP-300 for chronic hepatitis B, which is currently deprioritized pending partnership. In 2025, Barinthus restructured its operations, reducing headcount by approximately 65% and closing its UK site to focus on US operations and extend cash runway. The company announced a merger agreement with Clywedog, expected to close in 2026, to create a combined entity with a broader clinical-stage portfolio. Barinthus has no approved products and has incurred net losses, with a net loss of $66.4 million in 2025. It maintains strong liquidity with over $70 million in cash and equivalents as of year-end 2025.

Savara Inc operates as a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, with a focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Its sole product candidate, MOLBREEVI, is an inhaled biologic granulocyte-macrophage colony-stimulating factor (GM-CSF) designed to treat autoimmune PAP. The company has completed a pivotal Phase 3 clinical trial (IMPALA-2) and submitted a Biologics License Application (BLA) to the FDA. After an initial Refusal to File letter, Savara resubmitted the BLA and received Priority Review. MOLBREEVI has received multiple regulatory designations to facilitate development and review, including Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine. Savara operates primarily through outsourcing manufacturing and clinical operations, focusing its resources on research and development, regulatory activities, and preparing for potential commercialization. The company has incurred operating losses since inception and has no product revenue to date. It maintains a strong liquidity position with cash, cash equivalents, and short-term investments totaling approximately $235.7 million as of December 31, 2025. Savara's financial and operational activities are concentrated on advancing MOLBREEVI through regulatory approval and potential market introduction.

Kestrel Group Ltd is a specialty insurance program group formed in 2025 through the combination of Kestrel Group LLC and Maiden Holdings, Ltd. It operates primarily in two segments: Program Services and Legacy Reinsurance. The Program Services segment offers fronting services and issuing carrier capacity to insurance program managers, MGAs, reinsurers, and brokers, leveraging exclusive contracts with four AmTrust Insurance Carriers rated A- by A.M. Best. This segment generates fee income by providing access to the insurance carriers' rating, licensing, and reputation, typically charging fees averaging 5% of gross written premium. The business model relies on MGAs and capacity providers to handle underwriting, claims, and administration, enabling a capital-light approach with minimal incremental expenses. The Legacy Reinsurance segment manages run-off portfolios from Maiden's prior reinsurance business, including property and casualty reinsurance in Europe and other markets. The company reported $34.049 million in revenue and $46.725 million in net income for 2025, with a focus on growing fee income and managing legacy portfolios to optimize shareholder returns. Kestrel Group maintains liquidity through cash, investments, and asset disposition, while facing competition from other fronting service providers and regulatory and operational risks [S1][S2].

US Energy Corp is a U.S.-based company engaged primarily in the exploration and production of oil and natural gas, with operations concentrated in several U.S. regions including the Rockies, Mid-Continent, and Texas Gulf Coast areas. The company also has development-stage industrial gas assets, focusing on resource evaluation and permitting. It operates as a single reportable segment and uses the full cost accounting method for its oil and gas properties. Revenue is generated from the sale of oil, natural gas, and natural gas liquids, recognized upon transfer of custody to purchasers. The company maintains a revolving credit facility with FirstBank Southwest, which was amended in 2025 to extend maturity and adjust borrowing base. US Energy Corp reported a net loss in 2025 and has a working capital deficit, partially offset by available credit. Capital expenditures are focused on industrial gas property acquisition and development, with financing activities supported by equity offerings and credit facility borrowings. The company has remediated prior internal control weaknesses and maintains compliance with financial covenants.

Shimmick Corp delivers turnkey infrastructure solutions primarily in water markets and other critical infrastructure sectors such as energy, climate resilience, and sustainable transportation. The company has a long engineering heritage and operates mainly in California with projects in six other states. It self-performs many projects to control costs and risks. Its project backlog was approximately $793 million as of January 2026. Shimmick focuses on water and wastewater treatment, water resources infrastructure, climate resilience, transportation systems, and energy transition projects. The company launched Axia Electric LLC in 2025 to expand electrical infrastructure services. It employs selective bidding and collaborative contracting to manage project risk and improve margins. Shimmick reported a net loss for fiscal 2025 but has increased its bidding capacity and backlog during the year. The company maintains a strong safety culture and emphasizes environmental and social responsibility.